Guardian Pharmacy Services, Inc. Class A Common Stock (GRDN)

Guardian Pharmacy Services (NYSE:GRDN) reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.

Guardian Pharmacy Services (NYSE:GRDN) reported what executives described as a solid first quarter of 2026, with management saying the company successfully navigated the initial implementation of the Inflation Reduction Act’s new framework while maintaining its full-year revenue outlook and raising

Guardian (GRDN) Q1 2026 Earnings Transcript

Guardian Pharmacy (GRDN) Earnings Transcript

GRDN stock passes the Minervini Trend Template with strong technicals and high-growth momentum, showing powerful earnings growth and analyst upgrades.

Guardian Pharmacy Services (GRDN) aligns with Mark Minervini's momentum strategy, showing strong earnings growth of 139% and a bullish technical trend above key moving averages.

The relatively new healthcare stock was attracting positive attention for a good quarterly earnings report.

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Guardian Pharmacy Services acquires Mercury Pharmacy Services in Washington, expanding its presence in the Pacific Northwest and meeting growing demand for LTC support.

Truist initiates coverage of Guardian Pharmacy, projecting a $22 price target due to strong growth in the $24.8 billion institutional pharmacy market.